Screener
Revolution Medicines, Inc. RVMD EPS (Diluted)
EPS (Diluted) at other companies
Other financials
Where this comes from
Reported directly by Revolution Medicines, Inc. in its filing.
Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.
The source filing: Revolution Medicines, Inc.’s 10-Q, filed August 5, 2026. Open the filing →
- Filed
- Aug 5, 2026, 4:10 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-335104
FAQ
- What is Revolution Medicines, Inc.'s EPS (diluted)?
- Revolution Medicines, Inc. (RVMD) reported EPS (diluted) of -$3.06 in Q2 2026.
- How has Revolution Medicines, Inc.'s EPS (diluted) changed year-over-year?
- Revolution Medicines, Inc.'s EPS (diluted) decreased by 133.6% year-over-year, from -$1.31 to -$3.06.
- What is the long-term trend for Revolution Medicines, Inc.'s EPS (diluted)?
- Over 4 years (2021 to 2025), Revolution Medicines, Inc.'s EPS (diluted) has grown at a 23.3% compound annual growth rate (CAGR), from -$2.57 to -$5.94.
- What does EPS (diluted) mean?
- Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.
Ask your AI about Revolution Medicines, Inc.'s eps (diluted).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude